Medical Community Officially Renames PCOS to PMOS After Decade Long Campaign

Historic Name Change Addresses Decades of Confusion

After an unprecedented 11-year global effort, polycystic ovary syndrome (PCOS) was renamed polyendocrine metabolic ovarian syndrome (PMOS) in a landmark decision published in The Lancet. The name change, which involved hearing from 22,000 people , aims to correct a fundamental misunderstanding that has plagued women's healthcare for nearly a century.

The original name was deeply misleading. "There's no cysts in the ovary, so it's very confusing," explained Dr. Melanie Cree, a pediatric endocrinologist at the University of Colorado who worked on the renaming. The "cysts" seen on ultrasound are arrested follicles , not pathological cysts as the name implied. This confusion contributed to a staggering reality: up to 70% of people with the condition are undiagnosed .

PMOS impacts 1 in 8, or more than 170 million women worldwide . The condition causes irregular periods, weight gain, acne, excess hair growth, and significantly increases risks for diabetes and heart disease. Yet for decades, medical care has been fragmented, focusing primarily on reproductive issues while missing the broader metabolic implications.

Global Consensus Emerges From Patient Voices

The renaming process was extraordinary in its scope and inclusivity. The robust process generated representativeness, legitimacy, and transparency, with engagement of people with PCOS, health professionals, and 56 organisations across world regions . Out of 90 voters (including doctors, researchers, patients, advocates), 87 supported it immediately , making it nearly unanimous.

Patient advocates played crucial roles throughout the process. Rachel Morman, chair of Verity, a UK-based advocacy group, emphasized how "the new name now leads with hormones and recognizes the metabolic dimension of the condition" . Australian advocate Lorna Berry, who has PMOS, called the change "life changing" and said "It is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning."

The new terminology reflects scientific accuracy. Polyendocrine recognizes that the condition is underpinned by multiple interacting hormonal disturbances, including insulin, androgens, and neuroendocrine hormones , while metabolic acknowledges the inherent metabolic features such as insulin resistance, obesity, and increased risks for type 2 diabetes and cardiovascular disease .

Transforming Medical Practice and Patient Care

The implications extend far beyond semantics. "The majority of women don't get appropriate metabolic screening," and "serious health problems can be missed, sometimes for years" , according to Dr. Cree. This oversight is particularly concerning because "cardiovascular disease starts very early" in adolescents with PMOS.

The name change comes with a comprehensive implementation strategy. PMOS will be fully implemented in the 2028 International Guideline update , giving healthcare systems time to adapt. Medical professionals are already spreading awareness through conferences and medical societies to ensure the transition reaches practitioners worldwide.

The transformation promises to reshape how patients receive care. Instead of treatment focused primarily on fertility concerns, the new framework encourages comprehensive metabolic screening and management. This holistic approach could dramatically improve long-term health outcomes for millions of women who have struggled with fragmented care and delayed diagnoses. The change represents not just medical progress, but a validation of patient voices demanding accuracy and equity in healthcare.